Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Chronic Lymphocytic Leukemia Clinical Trials

A listing of Chronic Lymphocytic Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (35) clinical trials

A Phase 1 clinical study for patients with childhood ALL, Acute myeloid leukemia, Preleukemia, Chronic myeloid leukemia, MYELODYSPLASTIC SYNDROME

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability and identify a Maximum Tolerated Dose (MTD)/tentative Recommended Phase II Dose (RP2D) in subjects with refractory or relapsed Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in blast phase, or ...


Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Stage I - Pharmacokinetics (Bioequivalence) Subjects will be randomized to receive CC-486 300 mg orally on each of the two pharmacokinetic (PK) study days based on the dosing sequences they are randomized to: Dosing Sequence 1: 2x150 mg tablets followed by 1x30 mg tablet. Dosing Sequence 2: 1x300 mg tablet ...


Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

The purpose of this study is to evaluate the safety and tolerability of ascending doses of UCART19 in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL) and to determine the maximum tolerated dose (MTD).


A clinical trial to evaluate treatments using Ibrutinib, BI 836826 for patients with Chronic Lymphocytic Leukemia

Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, and who are eligible for treatment with ibrutinib. Objectives of the trial are to determine the recommended Phase 2 dose of BI 836826, ...


Biological Therapy in Treating Patients at High-Risk or With Lymphoma Lymphoproliferative Disease or Malignancies

The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.


A clinical trial seeking patients for a research study for the treatment of Blood disorder, Multiple Myeloma, MYELODYSPLASTIC SYNDROME, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia

Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and multiple myeloma (MM) can now be cured by allogeneic bone marrow transplantation (BMT). This curative effect has been ascribed to the use ...


Clinical Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Background Persons may be prone to develop hematologic or lymphoproliferative cancer for a variety of reasons including: inherited predisposition of benign, premalignant, or malignant conditions; environmental exposures shared by family members; previous tumors or preneoplastic conditions; immune deficiency; or stochastic processes Investigations of individuals and families at high risk of ...

Phase N/A

Kappa-CD28 T Lymphocytes Chronic Lymphocytic Leukemia B-cell Lymphoma or Multiple Myeloma CHARKALL

To prepare the lymphoma, MM or CLL specific T cells investigators will take 240 ml (up to 16 tablespoonfuls)of blood from the patient. This would be drawn as 2 (two) separate blood collections of 120 ml (up to 8 tablespoonfuls) of blood. To get the kappa antibody (with CD28) to ...


Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM) and Splenic Marginal Zone Lymphoma (SMZL)

The purpose of this protocol is to collect blood, tissue (bone marrow and lymph node biopsies) and/or imaging studies (PET and CT scans) from patients with monoclonal B cell lymphocytosis (MBL) chronic lymphocytic leukemia/small lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstr(SqrRoot)(Delta)m macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Assessments will be ...

Phase N/A

Patients are needed to participate in a clinical research study evaluating Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Busulfan, Pre-HCT Mesna on Days -2 and -1, Post-HCT Mesna, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Mycophenolate mofetil, Sirolimus, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Fludarabine, G-CSF, Pre-HCT Mesna on Days -5 and -4, Pre-HCT Mesna on Days -6 and -5

This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil (MMF) for graft versus host disease (GVHD) prophylaxis in patients with hematologic malignancies.